Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines

Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines

BACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines.METHODS: Patients on BPaL under operational research, or 9–11-mont...

Full description

Saved in:
Bibliographic Details
Main Authors: D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2024-06-01
Series:IJTLD Open
Subjects:
bedaquiline
pretomanid
linezolid
economic evaluation
cost analysis
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000006/art00002
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items